AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
17.7 C
New York
Monday, October 19, 2026

Tag: Johnson & Johnson

newssourceFORcompanycontentinformation1releasesmarket

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Fedora Pharmaceuticals Expands Scientific Advisory Board with Appointment of Drs. Michael Dudley, Keith Micetich, and Jürgen Bulitta

Drs. Michael N. Dudley, Keith A. Micetich, and Jürgen B. Bulitta join advisory board of renowned infectious disease leaders at Fedora Pharmaceuticals.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

The Expanding Frontier of Chemical Engineering: ChemE Show 2026 Opens June 9-10 in Houston

ExxonMobil, Eli Lilly, Johnson & Johnson, and Sinopec headline a two-day program where petrochemicals, pharma, and the energy transition convergeHOUSTON, June 3, 2026 /PRNewswire/...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025...

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

DRI Healthcare Reports Second Quarter 2025 Results

Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management functionPortfolio assets generate Total Income of $44.1...

ASCM Houston Chapter Presents “Navigating the Future – A Port of Houston Update” at Houston Maritime Center & Museum

HOUSTON, Aug. 13, 2025 /PRNewswire/ -- The ASCM Houston Chapter will host an exclusive professional development event, Navigating the Future – A Port of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsJohnson & Johnson

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers